Search
                    Omaha, NE Paid Clinical Trials
A listing of 590  clinical trials  in Omaha, NE  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            421 - 432 of 590
        
                There are currently 590 clinical trials in Omaha, Nebraska looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Nebraska Medical Center, Creighton University Medical Center, Nebraska Methodist Hospital and Alegent Health Bergan Mercy Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you. 
            
                                        Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    Featured Trial
                
                Cardiovascular Disease Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Cardiovascular Disease
    
    
                            Conditions: 
                                    
        
            
                        Cardiovascular Disease
                    
                                    
                
                                    The Impact of the Family Room App on Caregivers
                                
            
            
        Recruiting
                            
            
                Engaging families in patient care during serious illness can enhance care quality, reduce social isolation, boost satisfaction, and lower healthcare costs. However, active involvement of family caregivers remains limited because there are no evidence-based tools to guide clinicians on how to include them effectively. This study will test and refine previously developed point-of-care application, Family Room, and determine its effectiveness by comparison with a control group. A series of surveys...  Read More             
        
        
    Gender:
                ALL
            Ages:
                19 years and above
            Trial Updated:
                04/24/2025
            
            Locations: Nebraska Medicine, Omaha, Nebraska  +1 locations         
        
        
            Conditions: Well-Being, Psychological, Engagement, Satisfaction, Consumer
        
            
        
    
                
                                    Conditioning SCID Infants Diagnosed Early
                                
            
            
        Recruiting
                            
            
                The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related dono...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 0 years and 2 years
            Trial Updated:
                04/22/2025
            
            Locations: Nebraska Medicine, Omaha, Nebraska         
        
        
            Conditions: SCID
        
            
        
    
                
                                    DALY II USA/ MB-CART2019.1 for DLBCL
                                
            
            
        Recruiting
                            
            
                DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Additional cohorts include subjects with B-cell primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL), mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/21/2025
            
            Locations: University of Nebraska Medical Center, Omaha, Nebraska         
        
        
            Conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma, Mantle Cell Lymphoma (MCL), Richter Transformation
        
            
        
    
                
                                    Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
                                
            
            
        Recruiting
                            
            
                The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis...  Read More             
        
        
    Gender:
                MALE
            Ages:
                Between 18 years and 100 years
            Trial Updated:
                04/21/2025
            
            Locations: Urology Cancer Center PC, Omaha, Nebraska  +1 locations         
        
        
            Conditions: Prostate Cancer
        
            
        
    
                
                                    A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
                                
            
            
        Recruiting
                            
            
                This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSCLC patients with EGFR exon 20 insertion mutations,uncommon mutations, classical mutations (Ex19del and L858R), and drug-resistant mutation (T790M). Patients will be enrolled and dosed according to the most current protocol. This study is made of two Parts. Part 1 includes a dose escalation into 7 c...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/21/2025
            
            Locations: Nebraska Cancer Specialists, Omaha, Nebraska         
        
        
            Conditions: Non-Small Cell Lung Cancer
        
            
        
    
                
                                    A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
                                
            
            
        Recruiting
                            
            
                This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                04/15/2025
            
            Locations: University of Nebraska Medical Center, Omaha, Nebraska         
        
        
            Conditions: Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Severe Aplastic Anemia, Autoimmune Diseases
        
            
        
    
                
                                    Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
                                
            
            
        Recruiting
                            
            
                This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.             
        
        
    Gender:
                ALL
            Ages:
                30 years and below
            Trial Updated:
                04/14/2025
            
            Locations: Children's Hospital and Medical Center of Omaha, Omaha, Nebraska  +1 locations         
        
        
            Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
        
            
        
    
                
                                    The Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser)
                                
            
            
        Recruiting
                            
            
                Investigators are studying how a device called The Lung Master device can help people breathe better. The investigational device increases the amount of air our lungs can hold, which is important for overall lung health. The Lung Master is not approved by the FDA.
The study has two visits approximately one month apart. In the first visit participants will take a spirometry test, particularly forced vital capacity (FVC), to measure volume change in the lungs. Participants will take the investiga...  Read More             
        
        
    Gender:
                ALL
            Ages:
                19 years and above
            Trial Updated:
                04/14/2025
            
            Locations: Biomechanics Research Building, Omaha, Nebraska         
        
        
            
        
    
                
                                    PREVENT ALL ALS Study
                                
            
            
        Recruiting
                            
            
                The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is begin funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The cl...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/14/2025
            
            Locations: University of Nebraska Medical Center, Omaha, Nebraska         
        
        
            Conditions: Amyotrophic Lateral Sclerosis
        
            
        
    
                
                                    Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
                                
            
            
        Recruiting
                            
            
                The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/11/2025
            
            Locations: Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha, Nebraska         
        
        
            Conditions: Metastatic Urothelial Cancer
        
            
        
    
                
                                    Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
                                
            
            
        Recruiting
                            
            
                This is a multi-center clinical trial in Cytomegalovirus (CMV) seronegative prospective liver transplant recipients to determine the efficacy of two doses of Cytomegalovirus-Modified Vaccinia Ankara (CMV-MVA) Triplex CMV vaccine pre-transplant. The primary objective is to assess the effect of pre-transplant (Tx) Triplex vaccination on duration of CMV antiviral therapy (AVT) within the first 100 days post-Tx in CMV seropositive donor (D+) and seronegative (R-) (D+R-) liver transplant recipients (...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/11/2025
            
            Locations: University of Nebraska Medical Center, Omaha, Nebraska         
        
        
            Conditions: Liver Transplant
        
            
        
    
                
                                    ASSESS ALL ALS Study
                                
            
            
        Recruiting
                            
            
                The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The cl...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/11/2025
            
            Locations: University of Nebraska Medical Center, Omaha, Nebraska         
        
        
            Conditions: Amyotrophic Lateral Sclerosis
        
            
        
    421 - 432 of 590
            